Lori S. Jones

发表

Investigation of Metabolism and Disposition of GSK1322322, a Peptidase Deformylase Inhibitor, in Healthy Humans Using the Entero-Test for Biliary Sampling

Chester L. Bowen, O. Naderer, Liangfu Chen, 2014, Drug Metabolism and Disposition.

Pharmacokinetics of hepatitis C virus NS5A inhibitor JNJ‐56914845 (GSK2336805) in subjects with hepatic impairment

William Smith, K. Adkison, T. Marbury, 2015, Journal of clinical pharmacology.

Safety, Tolerability, and Efficacy of GSK1322322 in the Treatment of Acute Bacterial Skin and Skin Structure Infections

W. O'Riordan, O. Naderer, R. Corey, 2014, Antimicrobial Agents and Chemotherapy.

Safety , Tolerability , and Efficacy of GSK 1322322 in the Treatment of Acute Bacterial Skin and Skin Structure Infections

W. O'Riordan, O. Naderer, R. Corey, 2014 .

Penetration of GSK1322322 into Epithelial Lining Fluid and Alveolar Macrophages as Determined by Bronchoalveolar Lavage

Chester L. Bowen, O. Naderer, K. Rodvold, 2013, Antimicrobial Agents and Chemotherapy.

Zanamivir Pharmacokinetics and Pulmonary Penetration into Epithelial Lining Fluid following Intravenous or Oral Inhaled Administration to Healthy Adult Subjects

M. Shelton, K. Rodvold, Lori S. Jones, 2011, Antimicrobial Agents and Chemotherapy.

The Effect of Food and Formulation on the Pharmacokinetics, Safety, and Tolerability of GSK1322322 in Healthy Volunteers

O. Naderer, John Zhu, Lori S. Jones, 2014, Clinical pharmacology in drug development.

Safety, tolerability, and pharmacokinetics of oral and intravenous administration of GSK1322322, a peptide deformylase inhibitor

O. Naderer, John Zhu, Lori S. Jones, 2013, Journal of clinical pharmacology.

Safety, tolerability and pharmacokinetics of repeat dosing of the antibiotic GSK1322322, a peptide deformylase inhibitor: a randomized placebo-controlled study.

O. Naderer, John Zhu, Lori S. Jones, 2013, The Journal of antimicrobial chemotherapy.

Effect of H2 Blockade and Food on Single-Dose Pharmacokinetics of GSK1322322, a Peptide Deformylase Inhibitor Antibacterial

O. Naderer, John Zhu, Lori S. Jones, 2013, Antimicrobial Agents and Chemotherapy.

Single-Dose Safety, Tolerability, and Pharmacokinetics of the Antibiotic GSK1322322, a Novel Peptide Deformylase Inhibitor

O. Naderer, John Zhu, Lori S. Jones, 2013, Antimicrobial Agents and Chemotherapy.

Safety , tolerability and pharmacokinetics of repeat dosing of the antibiotic GSK 1322322 , a peptide deformylase inhibitor : a randomized placebo-controlled study

O. Naderer, John Zhu, Lori S. Jones, 2013 .

Pharmacokinetics of Zanamivir following Intravenous Administration to Subjects with and without Renal Impairment

S. Weller, Lori S. Jones, Y. Lou, 2013, Antimicrobial Agents and Chemotherapy.

Ritonavir Increases Plasma Amprenavir (APV) Exposure to a Similar Extent when Coadministered with either Fosamprenavir or APV

K. Baker, M. Shelton, Lori S. Jones, 2006, Antimicrobial Agents and Chemotherapy.

Microbiome Changes in Healthy Volunteers Treated with GSK 1322322 , a Novel Antibiotic Targeting Bacterial Peptide

James R. Brown, G. P. Livi, Elizabeth Thomas, 2015 .

Microbiome Changes in Healthy Volunteers Treated with GSK1322322, a Novel Antibiotic Targeting Bacterial Peptide Deformylase

James R. Brown, G. P. Livi, S. Van Horn, 2014, Antimicrobial Agents and Chemotherapy.

Effects of omeprazole and ritonavir on absorption and elimination of the hepatitis C virus NS5A inhibitor GSK2336805 in healthy adults

D. Wilfret, K. Adkison, Lori S. Jones, 2014, Clinical pharmacology in drug development.

Application of a Stable Isotope Approach to Evaluate Impact of Changes in Manufacturing Parameters for an Immediate‐Release Tablet

Alan Parr, Manish Gupta, Geoff Badman, 2016, Journal of clinical pharmacology.